Home/180 Life Sciences/Kevin J. Connors
KJ

Kevin J. Connors

Board Director

180 Life Sciences

180 Life Sciences Pipeline

DrugIndicationPhase
Anti-TNF (Local Administration)Dupuytren's Disease (Early Stage)Phase 2b
Synthetic Cannabinoid AnalogsChronic Pain & InflammationPre-clinical
α7nAChR ProgramInflammatory Bowel Disease (IBD) & Other Inflammatory ConditionsPre-clinical